Durvalumab immune checkpoint inhibition

Description Results NMA

combination of MEDI4736 (durvalumab) plus tremelimumab (n=-9)

vs.

Standard of Care (n=-9)

Sample size: -9/-9

Primary endpoint: Overall Survival ,

FU duration:

PFS 0.52 [0.42; 0.65] median 16.8 mo vs. 5.6 mo Demonstrated

Durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) every 2 weeks for up to 12 months, administered 1 to 42 days after the patients had received chemoradiotherapy (n=473)

vs.

placebo (n=236)

double-blind

Parallel groups

Sample size: 473/236

Primary endpoint: PFS, OS

FU duration:

durvalumab at 10 mg/kg body weight administered as an intravenous infusion over 60 minutes every two weeks until disease progression or unacceptable toxicity (n=-9)

vs.

(n=-9)

Single-arm study

Sample size: -9/-9

Primary endpoint:

FU duration:

phase 1/2